Known targets — ChEMBL curated mechanism
ACHEBDKRB2CHRM1CHRM2CHRM3CHRNA1CHRNB1CHRNDCHRNECHRNGGUCY1A1GUCY1A2GUCY1B1GUCY1B2NAMPTPTAFRSLC10A2SLC6A2SLC6A3TACR1dacAdacBdacCftsImrcAmrcBmrdA
The experimentally established mechanism targets of Hydrochloric Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRM1 known ✓ | P11229 | 1/20 | 0.42 |
| ▸ | MEN1 | O00255 | 1/20 | 0.62 |
| ▸ | USP2 | O75604 | 1/20 | 0.62 |
| ▸ | POLB | P06746 | 1/20 | 0.62 |
| ▸ | PPARG | P37231 | 1/20 | 0.62 |
| ▸ | BLM | P54132 | 1/20 | 0.62 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.62 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.62 |
| ▸ | NCOR2 | Q9Y618 | 1/20 | 0.62 |
| ▸ | P2RY6 | Q15077 | 1/20 | 0.55 |
| ▸ | TGM2 | P21980 | 1/20 | 0.48 |
| ▸ | FPR2 | P25090 | 4/20 | 0.46 |
| ▸ | ITPR1 | Q14643 | 1/20 | 0.44 |
| ▸ | AVPR2 | P30518 | 3/20 | 0.42 |
| ▸ | TLR7 | Q9NYK1 | 1/20 | 0.41 |
| ▸ | HTR3A | P46098 | 1/20 | 0.41 |
| ▸ | P2RY2 | P41231 | 1/20 | 0.40 |
| ▸ | SLC5A2 | P31639 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21878601 | 0.89 | USP2 (0.61) | MEN1USP2POLBPPARGBLM | |
| SCHEMBL20078093 | 0.88 | MEN1 (0.63) | MEN1USP2POLBPPARGBLM | |
| SCHEMBL21878599 | 0.87 | MEN1 (0.59) | MEN1USP2POLBPPARGBLM | |
| SCHEMBL16253380 | 0.86 | MEN1 (0.60) | MEN1USP2POLBPPARGBLM | |
| Hydrochloric Acid SCHEMBL30207638 | 0.83 | MEN1 (0.60) | MEN1USP2POLBPPARGBLM | |
| Hydrochloric Acid SCHEMBL29354092 | 0.83 | MEN1 (0.60) | MEN1USP2POLBPPARGBLM | |
| Hydrochloric Acid SCHEMBL18617 | 0.83 | MEN1 (0.60) | MEN1USP2POLBPPARGBLM | |
| SCHEMBL14547044 | 0.83 | MEN1 (0.56) | MEN1USP2POLBPPARGBLM | |
| Acetic Acid SCHEMBL29510237 | 0.82 | MEN1 (0.60) | MEN1USP2POLBPPARGBLM | |
| Hydrochloric Acid SCHEMBL31337069 | 0.82 | MEN1 (0.59) | MEN1USP2POLBPPARGBLM |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 159 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260132218-A1 | FULLY HUMAN MONOCLONAL ANTIBODIES AGAINST HUMAN HER-2 | A & G PHARMACEUTICAL INC (US) | 2026-05-14 | — | — | US | claimed |
| EP-4695300-A2 | ANTIBODIES AND CONJUGATES AGAINST PROSTAGLANDIN F2 RECEPTOR INHIBITOR AND USES THEREOF | A & G Pharmaceutical, Inc. (US) | 2026-02-18 | — | — | EP | claimed |
| EP-4224144-B1 | METHODS OF CALIBRATING A FLUORESCENCE-MEASURING INSTRUMENT FOR MEASURING LOW CONCENTRATIONS OF SOLUBLE MAGNESIUM | ECOLAB USA INC (US) | 2025-10-08 | — | — | EP | claimed |
| WO-2025133002-A1 | MICROPOROUS SIO2 PARTICLES | MERZ + BENTELI AG (CH) | 2025-06-26 | — | — | WO | claimed |
| US-20250154237-A1 | FULLY HUMAN MONOCLONAL ANTIBODIES AGAINST HUMAN PROGRANULIN | A & G PHARMACEUTICAL, INC. | 2025-05-15 | — | — | US | claimed |
| EP-4482861-A2 | FULLY HUMAN MONOCLONAL ANTIBODIES AGAINST HUMAN PROGRANULIN | A & G Pharmaceutical, Inc. (US) | 2025-01-01 | — | — | EP | claimed |
| CN-119156399-A | Fully human monoclonal antibodies against human granulin precursors | A&G 药品公司 | 2024-12-17 | — | — | CN | claimed |
| WO-2024215624-A2 | ANTIBODIES AND CONJUGATES AGAINST PROSTAGLANDIN F2 RECEPTOR INHIBITOR AND USES THEREOF | A & G PHARMACEUTICAL, INC. (US) | 2024-10-17 | — | — | WO | claimed |
| EP-4057887-B1 | METHOD OF VISUALIZING AND QUANTIFYING REMINERALIZATION | JOHNSON & JOHNSON CONSUMER INC (US) | 2024-08-14 | — | — | EP | claimed |
| WO-2024081905-A2 | FULLY HUMAN MONOCLONAL ANTIBODIES AGAINST HUMAN HER-2 | A & G PHARMACEUTICAL, INC. (US) | 2024-04-18 | — | — | WO | claimed |
| US-20230114871-A1 | LAYER-BY-LAYER ASSEMBLY OF GRAPHENE OXIDE MEMBRANES VIA ELECTROSTATIC INTERACTION AND ELUDICATION OF WATER AND SOLUTE TRANSPORT MECHANISMS | NATIONAL SCIENCE FOUNDATION | 2023-04-13 | — | — | US | claimed |
| WO-2022263638-A1 | ANTI-SARS-COV-2 ANTIBODIES AND USE THEREOF IN THE TREATMENT OF SARS-COV-2 INFECTION | CENTRE HOSPITALIER UNIVERSITAIRE VAUDOIS (C.H.U.V.) (CH) | 2022-12-22 | — | — | WO | claimed |
| US-11465398-B2 | Layer-by-layer assembly of graphene oxide membranes via electrostatic interaction and eludication of water and solute transport mechanisms | UNIVERSITY OF MARYLAND, COLLEGE PARK (US) | 2022-10-11 | — | — | US | claimed |
| US-20220267416-A1 | HIV BINDING AGENTS | LAUSANNE UNIVERSITY HOSPITAL (CH) | 2022-08-25 | — | — | US | claimed |
| CN-109983339-B | Method for estimating concentration of foundation injection agent | 株式会社竹中工务店 | 2022-08-05 | — | — | CN | claimed |
| WO-2022162587-A1 | ANTI-SARS-COV-2 ANTIBODIES AND USE THEREOF IN THE TREATMENT OF SARS-COV-2 INFECTION | CENTRE HOSPITALIER UNIVERSITAIRE VAUDOIS (C.H.U.V.) (CH) | 2022-08-04 | — | — | WO | claimed |
| EP-3996815-A2 | HIV BINDING AGENTS | LAUSANNE UNIVERSITY HOSPITAL (CH) | 2022-05-18 | — | — | EP | claimed |
| US-20220111050-A1 | BIOPHOTONIC COMPOSITIONS, METHODS, AND KITS FOR INHIBITING AND DISRUPTING BIOFILMS | FLE INTERNATIONAL S.R.L. (IT) | 2022-04-14 | — | — | US | claimed |
| CN-107771279-B | Calibration method for water hardness measurement | 艺康美国股份有限公司 | 2022-03-22 | — | — | CN | claimed |
| US-11231406-B2 | Ground injection agent concentration estimation method | TAKENAKA CORPORATION (JP) | 2022-01-25 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260132218-A1 | FULLY HUMAN MONOCLONAL ANTIBODIES AGAINST HUMAN HER-2 | IGSF11, IGLV6-57, FCGR2A | CHRM1 2213/4885MEN1 3831/4885USP2 873/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.